Hemostasis Today

April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
Apr 12, 2026, 17:34

Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow

Caitlin Raymond, Assistant Professor of Pathology and Transfusion Medicine at University of Wisconsin-Madison, shared a post on Linkedin:

New post: Granulocyte Transfusions for the Overworked Fellow.

Someone suggests granulocytes for your profoundly neutropenic, fungal-infected, not-responding patient. You nod. You place the consult. And somewhere in the back of your mind, a small voice asks: does this actually work?

That voice deserves an honest answer.

Here’s what the literature actually gives us:

  • The biological rationale is sound. No neutrophils, no innate immune response. Supplementing from the outside makes mechanistic sense.
  • The RING trial was the most rigorous attempt to test this — randomized, adequately powered, mortality endpoint. It didn’t show a survival benefit.
  • But RING had a problem: delivered doses were consistently below what’s considered therapeutic. If you can’t reliably deliver the intervention, you can’t cleanly interpret the result.
  • The amphotericin timing rule? Traced back to a single 1981 paper. Subsequent studies failed to replicate it. The practice outlived the evidence.
  • The 1 × 10¹⁰ dose target is real — but collection yields are variable, and hitting it is not guaranteed even with G-CSF and dexamethasone stimulation.

We have not arrived at a definitive answer on whether granulocyte transfusions improve survival. We tried hard to find out. The best trial we have had a fatal flaw in its ability to deliver the intervention reliably.

Knowing the limits of the evidence is not a failure of clinical knowledge. It is the clinical knowledge.”

Caitlin Raymond

Other posts featuring Caitlin Raymond on Hemostasis Today.